Infraredx Announces Launch of the New Advanced TVC Imaging System™ and TVC Muller Extended Bandwidth NIRS-IVUS Catheter™ at the American College of Cardiology (ACC) 2015 Annual Meeting

Research supporting the value of adding NIRS-IVUS imaging to intravascular cardiology practice for detecting coronary artery disease will be presented throughout the meeting

BURLINGTON, Mass.--()--Infraredx, a cardiovascular imaging company advancing the diagnosis and treatment of coronary artery disease, announced today that it will premiere the new Advanced TVC Imaging System™ and the Muller NIRS-IVUS Catheter™ featuring Extended Bandwidth IVUS™ technology at the American College of Cardiology’s 2015 Annual Scientific Meeting in San Diego from March 14-16 at booth #1215.

The Advanced TVC Imaging System is the only FDA-cleared technology capable of rapidly, specifically and reliably identifying lipid-core plaques (LCPs), which are known to complicate stenting procedures and suspected to cause most heart attacks1.

By integrating near-infrared spectroscopy (NIRS) with intravascular ultrasound (IVUS), the Advanced TVC Imaging System enables quick, informed clinical decision making and greater physician confidence in determining procedural and treatment strategies requiring information on vessel structure and plaque composition. This new, high-powered platform is designed to evolve with coronary care and incorporates advanced computing technology, the latest high-definition monitors, an intuitive, user-friendly interface and near-infrared laser optics for in vivo chemical analysis. This new system also includes Infraredx’s proprietary Extended Bandwidth IVUS technology, which represents the next generation in IVUS imaging. Extended Bandwidth ultrasound technology harmonizes multiple signal frequencies to produce a sharp image of the complete vessel that allows for easy identification of the lumen, plaque and vessel structure.

At the 64th Annual ACC Scientific Session, imaging and Infraredx’s TVC Imaging System will be discussed throughout the following sessions:

  • Sunday, March 15, 2015:
    • FFR/IVUS/OCT: Which One to Pick and When?
      • Presented by Morton J. Kern, MD, in Room 6F at 8:45 AM
    • Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During PCI
      • Presented by Annapoorna Subhash Kini, MD, in Poster Hall B1 2102-276 at 9:45 AM
    • In Vivo Verification of Lipid Detection by Near-Infrared Spectroscopy in Calcified Lesions—Comparison with Optical Coherence Tomography
      • Presented by Sadako Motoyama, MD, PhD, in ACC-12 Moderated Session Poster Hall B1-21030-272 at 3:45 PM
  • Monday, March 16, 2015
    • The Impact of Lipid-Containing Plaque Composition Measured by Near-Infrared Spectroscopy on Coronary Arterial Remodeling
      • Presented by Hideaki Ota, MD, in Poster Hall B1-2104-289 at 9:45 AM
    • Classifying Plaques According to Lipid Content As Assessed by Near Infrared Spectroscopy: Implications for Plaque Vulnerability
      • Presented by Annapoorna Subhash Kini, MD, in Poster Hall B1-2104-312 at 9:45 AM

In addition, a meeting of the Lipid-rich Plaque Study investigators will be held. This multicenter study is designed to test the hypothesis that TVC imaging can identify the plaques likely to cause a heart attack. The study already has over 850 patients enrolled and is expected to yield a result in late 2015.

“Over the past 25 years, there have been few technological innovations in intravascular imaging systems that compare with those introduced in the TVC Imaging Systems,” said Don Southard, CEO of Infraredx. “Understanding vessel structure and plaque composition is critically important for interventional cardiologists. The Advanced TVC Imaging System will assist physicians to achieve their goal of optimizing PCI procedures. At the ACC Annual Meeting, we look forward to unveiling our latest advancements, which we believe will be of great value for the care of coronary patients, and move closer to the goal of preventing the initial onset of heart attacks.”

About The Advanced TVC Imaging System™

The Advanced TVC Imaging System is a first-in-class intravascular imaging system designed to improve the management of coronary artery disease by providing information critical to the evaluation of vessel structure and plaque composition, also known as true vessel characterization. The Advanced TVC Imaging System helps interventional cardiologists identify which patients are at high-risk for complications during stenting. The device enables cardiologists to predict the risk of peri-procedural heart attacks by assessing not only the degree of stenosis, but also the presence and extent of lipid-core plaques (LCPs).

The device is the only commercially available multimodality imaging system to combine both intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS). Through Extended Bandwidth IVUS™ technology, the Advanced TVC Imaging System provides a clear, high quality image to provide important information about vessel structure and plaque composition in real time. The TVC Imaging System is the only device specifically approved for the detection of LCPs. NIRS measurements have been made in more than 14,000 patients in over 100 hospitals worldwide.

About Infraredx, Inc.

Infraredx, Inc. is a cardiovascular imaging company advancing the diagnosis and treatment of coronary artery disease, the world's leading cause of death according to the World Health Organization. Our dual-modality Advanced TVC Imaging System™ integrates near-infrared spectroscopy with intravascular ultrasound and is designed to provide physicians with information that has the potential to improve patient clinical outcomes through more tailored treatments. Founded in 1999, Infraredx is headquartered in Burlington, Massachusetts.

1 Prasad A, et. al. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol. 2009;54:477– 486.

Contacts

Infraredx, Inc.
Grant Frazier, 781-345-9632
Vice President of Marketing
gfrazier@infraredx.com
or
Racepoint Global
Mary Alfieri, 413-297-0105
infraredx@racepointglobal.com

Contacts

Infraredx, Inc.
Grant Frazier, 781-345-9632
Vice President of Marketing
gfrazier@infraredx.com
or
Racepoint Global
Mary Alfieri, 413-297-0105
infraredx@racepointglobal.com